AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive: Previous studies reported targeting the PI3K/AKT pathway sensitizes CML LSCs to therapy, providing further support for the claim that HULC contributes to IM resistance by increasing phosphorylation of the PI3K/AKT pathway [128].